Non-alcoholic steatohepatitis: an overview including treatments with herbals as alternative therapeutics

Journal of Applied Biomedicine

Volumn 10, Issue 3, 2012, Pages 119-136

  Thounaojam, Menaka Chanu ^a   Navalsinh Jadeja, Ravirajsinh ^a   Vijaysinh Devkar, Ranjisinh ^a   Vadathala Ramachandran, Ayalur ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

herbal medicine; non alcoholic steatohepatitis; phytocompounds; polyherbal formulation

Indexed keywords

HERBACEOUS AGENT; PLANT EXTRACT;

ALTERNATIVE MEDICINE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIET THERAPY; ENVIRONMENT; ETHNICITY; GENETICS; HERBAL MEDICINE; HISTORY OF MEDICINE; HUMAN; LIFESTYLE MODIFICATION; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR;

EID: 84870388034     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.2478/v10136-012-0008-9     Document Type: Review

References (151)

1. Adams, LA, Feldstein, AE, Nonalcoholic steatohepatitis: risk factors and diagnosis: metabolic risk factors for NASH. Expert Rev Gastroenterol Hepatol 4 (2010), 623–635.
2. Ahmed, LA, Ramadan, RS, Mohamed, RA, Biochemical and histopathological studies on the water extracts of marjoram and chicory herbs and their mixture in obese rats. Pak J Nutr 8 (2009), 1581–1587.
3. Amarapurkar, DN, Hashimoto, E, Lesmana, LA, Sollano, JD, Chen, P, Goh, KL, How common is non-alcoholic fatty liver disease in the Asia-Pacific region, and are there local differences?. J Gastroenterol Hepatol 22 (2007), 788–793.
4. Amini, R, Nosrati, N, Yazdanparast, R, Molaei, M, Teucrium polium in prevention of steatohepatitis in rats. Liver Int 29 (2009), 1216–1221.
5. Angulo, P, Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
6. Bacon, BR, Farahvash, MJ, Janney, CG, Neuschwander-Tetri, BA, Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107 (1994), 1103–1109.
7. Bahcecioglu, IH, Kuzu, N, Metin, K, Ozercan, IH, Ustündag, B, Sahin, K, Kucuk, O, Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet. Vet Med Int, 2010, 10.4061/2010/262179 2010.
8. Barker, DJ, Fetal programming of coronary heart disease. Trends Endocrinol Metab 13 (2002), 364–368.
9. Baxi, DB, Singh, PK, Vachhrajani, KD, Ramachandran, AV, Diabetic glucose dyshomeostasis and dyslipidemia in estrogen deficient rats: melatonin Supplementation more potent than estrogen replacement therapy in alleviating the symptoms. Diabetol Croat 40 (2011), 1–13.
10. Belfort, R, Harrison, SA, Brown, K, Darland, C, Finch, J, Hardies, J, Balas, B, Gastaldelli, A, Tio, F, Pulcini, J, Berria, R, Ma, JZ, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
11. Bose, M, Lambert, JD, Ju, J, Reuhl, KR, Shapses, SA, Yang, CS, The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 138 (2008), 1677–1683.
12. Browning, JD, Horton, JD, Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004), 147–152.
13. Browning, JD, Szczepaniak, LS, Dobbins, R, Nuremberg, P, Horton, JD, Cohen, JC, Grundy, SM, Hobbs, HH, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
14. Bruno, RS, Dugan, CE, Smyth, JA, DiNatale, DA, Koo, SI, Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J Nutr 138 (2008), 323–331.
15. Bujanda, L, Hijona, E, Larzabal, M, Beraza, M, Aldazabal, P, García-Urkia, N, Sarasqueta, C, Cosme, A, Irastorza, B, González, A, Arenas, JI Jr., Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol, 8, 2008, 40.
16. Cai, S, Huang, C, Ji, B, Zhou, F, Wise, ML, Zhang, D, Yang, P, In vitro antioxidant activity and inhibitory effect, on oleic acid-induced hepatic steatosis, of fractions and subfractions from oat (Avena sativa L.) ethanol extract. Food Chem 124 (2011), 900–905.
17. Caldwell, SH, Harris, DM, Patrie, JT, Hespenheide, EE, Is NASH underdiagnosed among African Americans?. Am J Gastroenterol 97 (2002), 1496–1500.
18. Carmiel-Haggai, M, Cederbaum, AI, Nieto, N, A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19 (2005), 136–138.
19. Chan, DF, Li, AM, Chu, WC, Chan, MH, Wong, EM, Liu, EK, Chan, IH, Yin, J, Lam, CW, Fok, TF, Nelson, EA, Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 28 (2004), 1257–1263.
20. Chande, N, Laidlaw, M, Adams, P, Marotta, P, Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci 51 (2006), 1183–1189.
21. Charlton, M, Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2 (2004), 1048–1058.
22. Chidambaram, J, Carani Venkatraman, A, Cissus quadrangularis stem alleviates insulin resistance, oxidative injury and fatty liver disease in rats fed high fat plus fructose diet. Food Chem Toxicol 48 (2010), 2021–2029.
23. Chou, SC, Chen, KW, Hwang, JS, Lu, WT, Chu, YY, Lin, JD, Chang, HJ, See, LC, The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease. Altern Ther Health Med 12 (2006), 34–39.
24. Cui, W, Chen, SL, Hu, KQ, Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2 (2010), 95–104.
25. Day, CP, James, OF, Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
26. Day, CP, Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?. Gut 50 (2002), 585–588.
27. de Lima, VM, de Oliveira, CP, Sawada, LY, Barbeiro, HV, de Mello, ES, Soriano, FG, Alves, VA, Caldwell, SH, Carrilho, FJ, Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet. Liver Int 27 (2007), 227–234.
28. de Oliveira, CPMS, de Lima, VMR, Simplicio, FI, Soriano, FG, de Mello, ES, de Souza, HP, Alves, VAF, Laurindo, FRM, Carrilho, FJ, de Oliveira, MG, Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment. J Am Coll Nutr 27 (2008), 299–305.
29. Diehl, AM, Nonalcoholic steatosis. Sem Liv Dis 19 (1999), 221–229.
30. Dixon, JB, Bhathal, PS, Jonsson, JR, Dixon, AF, Powell, EE, O'Brien, PE, Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 39 (2003), 967–971.
31. Dongiovanni, P, Valenti, L, Rametta, R, Daly, AK, Nobili, V, Mozzi, E, Leathart, JB, Pietrobattista, A, Burt, AD, Maggioni, M, Fracanzani, AL, Lattuada, E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59 (2010), 267–273.
32. Dowman, JK, Tomlinson, JW, Newsome, PN, Pathogenesis of non-alcoholic fatty liver disease. QJM 103 (2010), 71–83.
33. Dowman, JK, Tomlinson, JW, Newsome, PN, Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33 (2011), 525–540.
34. Edmison, J, McCullough, AJ, Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 11 (2007), 75–104.
35. Erickson, SK, Nonalcoholic fatty liver disease (NAFLD). J Lipid Res 50 (2009), S412–S416.
36. Ersöz, G, Günşar, F, Karasu, Z, Akay, S, Batur, Y, Akarca, US, Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 16 (2005), 124–128.
37. Fan, J, What are the risk factors and settings for NAFLD in Asia Pacific? The Consensus on NAFLD/NASH, 2006, APDW, Cebu.
38. Fan, JG, Qiao, L, Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 8 (2009), 233–240.
39. Fan, JG, Saibara, T, Chitturi, S, Sung, JJY, Kim, BI, Chutaputti, A, The Asia-Pacific working party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?. J Gastroenterol Hepatol 22 (2007), 794–800.
40. Fan, JG, Jia, J, Li, YM, Wang, BY, Lu, LG, Shi, JP, Chan, LY, Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. J Dig Dis 12 (2011), 38–44.
41. Foster, T, Budoff, MJ, Saab, S, Ahmadi, N, Gordon, C, Guerci, AD, Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106 (2011), 71–77.
42. Fu, JH, Sun, HS, Wang, Y, Zheng, WQ, Shi, ZY, Wang, QJ, The effects of a fat- and sugar-enriched diet and chronic stress on nonalcoholic fatty liver disease in male Wistar rats. Dig Dis Sci 55 (2010), 2227–2236.
43. Fujimoto, M, Tsuneyama, K, Kainuma, M, Sekiya, N, Goto, H, Takano, Y, Terasawa, K, Selmi, C, Gershwin, ME, Shimada, Y, Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver. Exp Biol Med 233 (2008), 328–337.
44. Fujimoto, M, Tsuneyama, K, Kinoshita, H, Goto, H, Takano, Y, Selmi, C, Keen, CL, Gershwin, ME, Shimada, Y, The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. Ann N Y Acad Sci 1190 (2010), 151–158.
45. Haddad, Y, Vallerand, D, Brault, A, Pierre, S, Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. eCAM, 2011, 10.1093/ecam/-nep164.
46. Hajaghamohammadi, AA, Ziaee, A, Rafiei, R, The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial. Hepat Mon 8 (2008), 191–195.
47. Hajiani, E, Hashemi, SJ, Comparison of therapeutic effects of silymarin and vitamin E in nonalcoholic fatty liver disease: results of an open-labele, prospective, randomized study. Jundishapur J Nat Pharm Prod 40 (2009), 8–14.
48. Hales, CN, Barker, DJ, The thrifty phenotype hypothesis. Br Med Bull 60 (2001), 5–20.
49. Harish, K, Thomas, V, Non-alcoholic fatty liver disease in Asians – An emerging problem. Calcutta Med J, 6, 2008, e6.
50. Harrison, SA, Torgerson, S, Hayashi, P, Ward, J, Schenker, S, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98 (2003), 2485–2490.
51. Harrison, SA, Fincke, C, Helinski, D, Torgerson, S, Hayashi, P, A pilot study of orlistat treatment in obese, nonalcoholic steatohepatitis patients. Aliment Pharmacol Ther 20 (2004), 623–628.
52. Hashemi, SJ, Hajiani, E, Sardabi, EH, A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepatitis Monthly 9 (2009), 265–270.
53. Honda, H, Ikejima, K, Hirose, M, Yoshikawa, M, Lang, T, Enomoto, N, Kitamura, T, Takei, Y, Sato, N, Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36 (2002), 12–21.
54. Hong, X, Tang, H, Wu, L, Li, L, Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. J Pharm Pharmacol 58 (2006), 1391–1398.
55. Hsu, CL, Yen, GC, Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br J Nutr 98 (2007), 727–735.
56. Huang, TH, Peng, G, Li, GQ, Yamahara, J, Roufogalis, BD, Li, Y, Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-α. Toxicol Appl Pharmacol 210 (2006), 225–235.
57. Hussein, O, Grosovski, M, Schlesinger, S, Szvalb, S, Assy, N, Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 52 (2007), 2512–2519.
58. Itoh, S, Yougel, T, Kawagoe, K, Comparison between alcoholic and nonalcoholic hepatitis. Am J Gastroenterol, 82, 1987, 650.
59. Iwu, MM, Duncan, AR, Okunji, CO, New antimicrobials of plant origin. Janick, J, (eds.) Perspectives on New Crops and New Uses, 1999, ASHS Press, Alexandria, 457.
60. Jadeja, RN, Thounaojam, MC, Ansarullah, Devkar, RV, Ramachandran, AV, A preliminary study on hypolipidemic effect of aqueous leaf extract of Clerodendron glandulosum Coleb. Int J Green Pharm 3 (2009), 285–289.
61. Jadeja, RN, Thounaojam, MC, Ansarullah, Devkar, RV, Ramchandran, AV, Clerodendron glandulosum Coleb., Verbenaceae, ameliorates high fat diet-induced alteration in lipid and cholesterol metabolism in rats. Rev Bras Farmacogn 20 (2010), 117–123.
62. Jadeja, RN, Thounaojam, MC, Ansarullah, Patel, VB, Devkar, RV, Ramachandran, AV, Protective effect of Clerodendron glandulosum extract against experimentally induced metabolic syndrome in rats. Pharm Biol 48 (2010), 1312–1319.
63. Jadeja, RN, Thounaojam, MC, Dandekar, DS, Devkar, RV, Ramachandran, AV, Clerodendron glandulosum Coleb. extract ameliorates high fat diet/fatty acid induced lipotoxicity in experimental models of non alcoholic steatohepatitis. Food Chem Toxicol 48 (2010), 3424–3431.
64. Jadeja, RN, Thounaojam, MC, Devkar, RV, Ramachandran, AV, Clerodendron glandulosum Coleb. extract prevents in vitro human LDL oxidation and oxidized LDL induced apoptosis in human monocyte derived macrophages. Food Chem Toxicol 49 (2011), 1195–1202.
65. Jadeja, RN, Thounaojam, MC, Ramani, UV, Devkar, RV, Ramachandran, AV, Anti-obesity potential of Clerodendron glandulosum Coleb. leaf aqueous extract. J Ethnopharmacol 135 (2011), 338–343.
66. Jadeja, RN, Thounaojam, MC, Ansarullah, Jadav, SV, Patel, MD, Patel, DK, Salunke, SP, Padate, GS, Devkar, RV, Ramachandran, AV, Toxicological evaluation and hepatoprotective potential of Clerodendron glandulosum Coleb. leaf extract. Hum Exp Toxicol 30 (2011), 63–70.
67. Jou, J, Choi, SS, Diehl, AM, Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28 (2008), 370–379.
68. Kamboj, VP, Herbal medicine. Curr Sci, 78, 2000, 1.
69. Kershaw, EE, Flier, JS, Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004), 2548–2556.
70. Khoshbaten, M, Aliasgarzadeh, A, Masnadi, K, Farhang, S, Tarzamani, MK, Babaei, H, Kiani, J, Zaare, M, Najafipoor, F, Grape seed extract to improve liver function in patients with nonalcoholic fatty liver change. Saudi J Gastroenterol 16 (2010), 194–197.
71. Kohjima, M, Enjoji, M, Higuchi, N, Kato, M, Kotoh, K, Nakashima, M, Nakamuta, M, The effects of unsaturated fatty acids on lipid metabolism in HepG2 cells. In Vitro Cell Dev Biol Anim 45 (2009), 6–9.
72. Kuzu, N, Bahcecioglu, IH, Dagli, AF, Ozercan, IH, Ustündag, B, Sahin, K, Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J Gastroenterol Hepatol 23 (2008), e465–e470.
73. Larter, CZ, Yeh, MM, Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23 (2008), 1635–1648.
74. Lazo, M, Clark, JM, The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis 28 (2008), 339–350.
75. Leevy, CM, Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine, 41, 1962, 249.
76. Leuschner, UF, Lindenthal, B, Herrmann, G, Arnold, JC, Rössle, M, Cordes, HJ, Zeuzem, S, Hein, J, Berg, T, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52 (2010), 472–479.
77. Lewis, JR, Mohanty, SR, Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55 (2010), 560–578.
78. Li, Z, Yang, S, Lin, H, Huang, J, Watkins, PA, Moser, AB, Desimone, C, Song, XY, Diehl, AM, Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 (2003), 343–350.
79. Li, Z, Srivastava, S, Yang, X, Mittal, S, Norton, P, Resau, J, Haab, B, Chan, C, A hierarchical approach employing metabolic and gene expression profiles to identify the pathways that confer cytotoxicity in HepG2 cells. BMC Syst Biol 11 (2007), 1–21.
80. Lin, CL, Huang, HC, Lin, JK, Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res 48 (2007), 2334–2343.
81. Lin, MC, Kao, SH, Chung, PJ, Chan, KC, Yang, MY, Wang, CJ, Improvement for high fat diet-induced hepatic injuries and oxidative stress by flavonoid-enriched extract from Nelumbo nucifera leaf. J Agric Food Chem 57 (2009), 5925–5932.
82. Lirussi, F, Azzalini, L, Orando, S, Orlando, R, Angelico, F, Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev, 24, 2007 CD004996.
83. Lou, SY, Liu, Y, Ma, YY, Chen, HY, Chen, WH, Ying, J, He, YM, Wang, WJ, Effects of Yiqi Sanju Formula on non-alcoholic fatty liver disease: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 6 (2008), 793–798.
84. Ludwig, J, Viggiano, TR, McGill, DB, OH, BJ, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
85. Manco, M, Marcellini, M, DeVito, R, Comparcola, D, Sartorelli, MR, Nobili, V, Metabolic syndrome and liver histology in paediatric nonalcoholic steatohepatitis. Int J Obes 32 (2008), 381–387.
86. Matteoni, CA, Younossi, ZM, Gramlich, T, Boparai, N, Liu, YC, McCullough, AJ, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol 116 (1999), 1413–1419.
87. McPherson, S, Stewart, SF, Henderson, E, Burt, AD, Day, CP, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59 (2010), 1265–1269.
88. Mori, A, Takayama, F, Kawasaki, H, Nakamoto, K, Mankura, M, Ogino, T, Egashira, T, Hidaka, Y, Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis. J Clin Biochem Nutr 44 (2009), 239–246.
89. Musso, G, Gambino, R, De Michieli, F, Durazzo, M, Pagano, G, Cassader, M, Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 47 (2008), 1167–1177.
90. Neuschwander-Tetri, BA, Caldwell, SH, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 (2003), 1202–1219.
91. Nobili, V, Manco, M, Devito, R, Ciampalini, P, Piemonte, F, Marcellini, M, Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 24 (2006), 1553–1561.
92. Noh, JR, Kim, YH, Gang, GT, Yang, KJ, Kim, SK, Ryu, SY, Kim, YS, Lee, CH, Lee, HS, Preventative effects of Platycodon grandiflorum treatment on hepatic steatosis in high fat diet-fed C57BL/6 mice. Biol Pharm Bull 33 (2010), 450–454.
93. Nosrati, N, Aghazadeh, S, Yazdanparast, R, Effects of Teucrium polium on insulin resistance in nonalcoholic steatohepatitis. J Acupunc Merid Stud 3 (2010), 104–110.
94. Okita, M, Hayashi, M, Sasagawa, T, Takagi, K, Suzuki, K, Kinoyama, S, Ito, T, Yamada, G, Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 17 (2001), 542–547.
95. Oliveira, CP, Gayotto, LC, Tatai, C, Della Nina, BI, Lima, ES, Abdalla, DS, Lopasso, FP, Laurindo, FR, Carrilho, FJ, Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr J 7 (2003), 2–9.
96. Omagari, K, Kato, S, Tsuneyama, K, Hatta, H, Sato, M, Hamasaki, M, Sadakane, Y, Tashiro, T, Fukuhata, M, Miyata, Y, Tamaru, S, Tanaka, K, Mune, M, Olive leaf extract prevents spontaneous occurrence of non-alcoholic steatohepatitis in SHR/NDmcr-cp rats. Pathology 42 (2010), 66–72.
97. Osterreicher, CH, Brenner, DA, The genetics of nonalcoholic fatty liver disease. Ann Hepatol 6 (2007), 83–88.
98. Oz, HS, Chen, TS, Neuman, M, Methionine deficiency and hepatic injury in a dietary steatohepatitis model. Dig Dis Sci 53 (2008), 767–776.
99. Park, HJ, DiNatale, DA, Chung, MY, Park, YK, Lee, JY, Koo, SI, O'Connor, M, Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem 22 (2011), 393–400.
100. Park, SH, Lee, SG, Kang, SK, Chung, SH, Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice. Arch Pharm Res 29 (2006), 768–776.
101. Patel, T, Lee, JG, Fatty liver. eMed J, 2, 2001, 8.
102. Pessayre, D, Fromenty, B, Mansouri, A, Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 16 (2004), 1095–1105.
103. Petta, S, Muratore, C, Craxi, A, Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis 41 (2009), 615–625.
104. Pradhan, SC, Girish, C, Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124 (2006), 491–504.
105. Raju, J, Bird, RP, Alleviation of hepatic steatosis accompanied by modulation of plasma and liver TNF-α levels by Trigonella foenum graecum (fenugreek) seeds in Zucker obese (fa/fa) rats. Int J Obes 30 (2006), 1298–1307.
106. Ramalho, RM, Cortez-Pinto, H, Castro, RE, Solá, S, Costa, A, Moura, MC, Camilo, ME, Rodrigues, CM, Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 18 (2006), 21–29.
107. Rates, SMK, Plants as source of drugs. Toxicon 39 (2001), 603–613.
108. Ratziu, V, Charlotte, F, Heurtier, A, Gombert, S, Giral, P, Bruckert, E, Grimaldi, A, Capron, F, Poynard, T, LIDO Study Group, Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005), 1898–1906.
109. Rinella, ME, Elias, MS, Smolak, RR, Fu, T, Borensztajn, J, Green, RM, Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49 (2008), 1068–1076.
110. Romeo, SJ, Kozlitina, C, Xing, A, Pertsemlidis, D, Cox, LA, Pennacchio, E, Boerwinkle, J, Cohen, C, Hobbs, HH, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2000), 1461–1465.
111. Roskams, T, Yang, SQ, Koteish, A, Durnez, A, DeVos, R, Huang, X, Achten, R, Verslype, C, Diehl, AM, Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 163 (2003), 1301–1311.
112. Sahoo, N, Manchikanti, P, Dey, S, Herbal drugs: standards and regulation. Fitoterapia 81 (2010), 462–471.
113. Sanyal, AJ, Chalasani, N, Kowdley, KV, McCullough, A, Diehl, AM, Bass, NM, Neuschwander-Tetri, BA, Lavine, JE, Tonascia, J, Unalp, A, Van Natta, M, Clark, J, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
114. Sartorio, A, Del Col, A, Agosti, F, Mazzilli, G, Bellentani, S, Tiribelli, C, Bedogni, G, Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 61 (2007), 877–883.
115. Shen, B, Yu, J, Wang, S, Chu, ES, Wong, VW, Zhou, X, Lin, G, Sung, JJ, Chan, HL, Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology 47 (2008), 473–483.
116. Shetty, SN, Mengi, S, Vaidya, R, Vaidya, AD, A study of standardized extracts of Picrorhiza kurroa Royle ex Benth. in experimental nonalcoholic fatty liver disease. J Ayurveda Integr Med 1 (2010), 203–210.
117. Shiota, G, Tsuchiya, Pathphysiology of NASH: Insulin resistance, free fatty acids and oxidative stress. J Clin Biochem Nutr 38 (2006), 127–132.
118. Stefano, JT, de Oliveira, CP, Corrêa-Giannella, ML, de Lima, VM, de Sá, SV, de Oliveira, EP, de Mello, ES, Giannella-Neto, D, Alves, VA, Carrilho, FJ, Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig Dis Sci 52 (2007), 3448–3454.
119. th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, 2008.
120. Strauss, RS, Barlow, SE, Dietz, WH, Prevalence of abnormal serum amino transferase values in overweight and obese adolescents. J Pediatr 136 (2000), 727–733.
121. Tahan, V, Eren, F, Avsar, E, Yavuz, D, Yuksel, M, Emekli, E, Imeryuz, N, Celikel, C, Uzun, H, Haklar, G, Tozun, N, Rosiglitazone Attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci 52 (2007), 3465–3472.
122. Takayama, F, Egashira, T, Kawasaki, H, Mankura, M, Nakamoto, K, Okada, S, Mori, A, A Novel animal model of nonalcoholic steatohepatitis (NASH): hypoxemia enhances the development of NASH. J Clin Biochem Nutr 45 (2009), 335–340.
123. Takayama, F, Nakamoto, K, Kawasaki, H, Mankura, M, Egashira, T, Ueki, K, Hasegawa, A, Okada, S, Mori, A, Beneficial effects of Vitis coignetiae Pulliat leaves on nonalcoholic steatohepatitis in a rat model. Acta Med Okayama 63 (2009), 105–111.
124. Targher, G, Bertolini, L, Rodella, S, Zoppini, G, Scala, L, Zenari, L, Falezza, G, Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 64 (2006), 679–683.
125. Thounaojam, M, Jadeja, R, Ansarullah, Devkar, R, Ramachandran, AV, Dysregulation of lipid and cholesterol metabolism in high fat diet fed hyperlipidemic rats: Protective effect of Sida rhomboidea Roxb. leaf extract. J Health Sci 55 (2009), 413–420.
126. Thounaojam, MC, Jadeja, RN, Ansarullah, Devkar, RV, Ramachandran, AV, Prevention of high fat diet induced insulin resistance in C57/BL/6J mice by Sida rhomboidea Roxb. extract. J Health Sci 56 (2010), 92–98.
127. Thounaojam, MC, Jadeja, RN, Patel, DK, Devkar, RV, Ramchandran, AV, Acute and sub chronic oral toxicity of Sida rhomboidea Roxb. leaf extract. J Complement Integ Med, 7, 2010, 1.
128. Thounaojam, MC, Jadeja, RN, Devkar, RV, Ramachandran, AV, Sida rhomboidea Roxb. extract alleviates pathophysiological changes in experimental in vivo and in vitro models of high fat diet/fatty acid induced non-alcoholic steatohepatitis. Exp Toxicol Pathol, 2010 In press.
129. Thounaojam, MC, Jadeja, RN, Ramani, UV, Devkar, RV, Ramachandran, AV, Sida rhomboidea Roxb. leaf extract down-regulates expression of PPARγ2 and leptin genes in high fat diet fed C57BL/6J mice and retards in vitro 3T3L1 pre-adipocyte differentiation. Int J Mol Sci 12 (2011), 4661–4677.
130. Thounaojam, MC, Jadeja, RN, Devkar, RV, Ramachandran, AV, In Vitro evidence for the protective role of Sida rhomboidea Roxb. extract against LDL oxidation and oxidized LDL induced apoptosis in human monocyte derived macrophages. Cardiovasc Toxicol 11 (2011), 168–179.
131. Tilg, H, Moschen, AR, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (2010), 1836–1846.
132. Vajro, P, Mandato, C, Franzese, A, Ciccimarra, E, Lucariello, S, Savoia, M, Capuano, G, Migliaro, F, Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 38 (2004), 48–55.
133. Valenti, L, Al-Serri, A, Daly, AK, Galmozzi, E, Rametta, R, Dongiovanni, P, Nobili, V, Mozzi, E, Roviaro, G, Vanni, E, Bugianesi, E, Maggioni, M, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1209–1217.
134. Velayudham, A, Dolganiuc, A, Ellis, M, Petrasek, J, Kodys, K, Mandrekar, P, Szabo, G, VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49 (2009), 989–997.
135. Vendemiale, G, Grattagliano, I, Caraceni, P, Caraccio, G, Domenicali, M, Dall'Agata, M, Trevisani, F, Guerrieri, F, Bernardi, M, Altomare, E, Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology 33 (2001), 808–815.
136. Wang, GL, Fu, YC, Xu, WC, Feng, YQ, Fang, SR, Zhou, XH, Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 380 (2009), 644–649.
137. WHO 1996. Guidelines for the Assessment of Herbal Medicines. WHO Expert Committee on Specification for Pharmaceutical Preparations. Technical Report Series No. 863. Geneva.
138. WHO, Guidelines for the Regulation of Herbal Medicines in the South-East Asia Region: Developed at the Regional Workshop on the Regulation of Herbal Medicines, Bangkok, and 24–26 June 2003, 2003, Regional office for South East Asia, World Health Organization, New Delhi.
139. nd March 2011).
140. Wilfred de Alwis, NM, Day, CP, Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 27 (2007), 44–54.
141. Willner, IR, Waters, B, Patil, SR, Reuben, A, Morelli, J, Riely, CA, Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol 96 (2001), 2957–2961.
142. Xu, A, Wang, Y, Keshaw, H, Xu, LY, Lam, KS, Cooper, GJ, The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003), 91–100.
143. Xu, KZ, Zhu, C, Kim, MS, Yamahara, J, Li, Y, Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity. J Ethnopharmacol 123 (2009), 280–287.
144. Xu, ZI, Fan, JG, Ding, XD, Qiao, L, Wang, GL, Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 55 (2010), 931–940.
145. Yang, SF, Tseng, JK, Chang, YY, Chen, YC, Flaxseed oil attenuates nonalcoholic fatty liver of hyperlipidemic hamsters. J Agric Food Chem 57 (2009), 5078–5083.
146. Yao, HR, Liu, J, Plumeri, D, Cao, YB, He, T, Lin, L, Li, Y, Jiang, YY, Li, J, Shang, J, Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res 3 (2011), 284–291.
147. Yoneda, M, Hotta, K, Nozaki, Y, Endo, H, Uchiyama, T, Mawatari, H, Iida, H, Kato, S, Fujita, K, Takahashi, H, Kirikoshi, H, Kobayashi, N, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 29 (2009), 1078–1085.
148. Yoshioka, S, Hamada, A, Jobu, K, Yokota, J, Onogawa, M, Kyotani, S, Miyamura, M, Saibara, T, Onishi, S, Nishioka, Y, Effects of Eriobotrya japonica seed extract on oxidative stress in rats with non-alcoholic steatohepatitis. J Pharm Pharmacol 62 (2010), 241–246.
149. Zhu, L, Luo, X, Jin, Z, Effect of resveratrol on serum and liver lipid profile and antioxidant activity in hyperlipidemia rats. Asian Australas J Anim Sci 21 (2008), 890–895.
150. Amini, R, Yazdanparast, R, Aghazadeh, S, Ghaffari, SH, Teucrium polium reversed the MCD diet-induced liver injury in rats. Hum Exp Toxicol 30 (2011), 1303–1312.
151. Nobili, V, Marcellini, M, Marchesini, G, Vanni, E, Manco, M, Villani, A, Bugianesi, E, Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care 30 (2007), 2638–2640.